This inventor holds 2 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Illumina Cambridge Limited. Active years: 2023-2026.
Company Filing History:
Years Active: 2023-2026
Title: The Innovations of Philip Balding
Introduction
Philip Balding is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of biotechnology, particularly in the area of polynucleotide sequencing. With a total of 2 patents to his name, Balding continues to push the boundaries of scientific research and innovation.
Latest Patents
One of Balding's latest patents is titled "PRIMER OLIGONUCLEOTIDE FOR SEQUENCING." This invention focuses on adding nucleotides during sequence detection. The method involves incubating unlabeled nucleotides with a cluster of template polynucleotide strands that share the same sequence while detecting the identity of previously added labeled nucleotides. The detection step allows time for the unlabeled nucleotides to be incorporated into the copy strands where the labeled nucleotide was not incorporated. Consequently, by the end of the detection step, most copy strands will be in phase and ready to incorporate the appropriate labeled nucleotide in the subsequent incorporation step.
Career Highlights
Balding is currently associated with Illumina Cambridge Limited, a company renowned for its advancements in genomic sequencing technologies. His work at Illumina has positioned him at the forefront of innovation in the biotechnology sector.
Collaborations
Some of his notable coworkers include Pietro Gatti-Lafranconi and Jonathan Mark Boutell. Their collaborative efforts contribute to the ongoing advancements in the field of genetic research.
Conclusion
Philip Balding's contributions to biotechnology through his patents and work at Illumina Cambridge Limited highlight his role as a key innovator in the field. His inventions continue to pave the way for advancements in polynucleotide sequencing and genetic research.